Literature DB >> 6198127

Concentrations of ceftriaxone in prostate adenoma tissue.

D Adam, K G Naber.   

Abstract

A total of 46 patients aged 59-84 who underwent transurethral resection of the prostate gland received 2 g of ceftriaxone intravenously at different points in time, ranging from 30 min to 74 h before the operation. The antibiotic concentration was determined in the serum as well as in the prostate adenoma tissue using microbiological methods after treating the tissue in a stomacher. 30 min after application, tissue concentrations were between 12.9 and 73.7 micrograms/g, and after 4 h still between 1.0 and 50.0 micrograms/g. Even after 48 h levels between 0.6 and 5.6 micrograms/g were found. Therefore ceftriaxone proved not only to have a long serum half-life as compared to other comparable cephalosporins, but also prolonged tissue concentrations, which justifies a single preoperative dose before transurethral resection of the prostate gland, as established by the clinical results described.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198127     DOI: 10.1159/000238237

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  8 in total

1.  Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy.

Authors:  C Martin; X Viviand; A Cottin; V Savelli; C Brousse; E Ragni; C Richaud; M N Mallet
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 4.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

5.  Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue.

Authors:  K G Naber; M Kinzig; D Adam; F Sörgel; A H Bajorski; R Kiehn
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

Review 6.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

7.  Antibiotic prophylaxis with intravenous ceftriaxone and fluoroquinolone reduces infectious complications after transrectal ultrasound-guided prostatic biopsy.

Authors:  Chunwoo Lee; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Myung-Soo Choo; Hanjong Ahn; Tai Young Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2015-06-02

8.  Ceftriaxone for the Treatment of Chronic Bacterial Prostatitis: A Case Series and Literature Review.

Authors:  Sander G Kuiper; Maarten Ploeger; Erik B Wilms; Marleen M van Dijk; Emiel Leegwater; Robert A G Huis In't Veld; Cees van Nieuwkoop
Journal:  Antibiotics (Basel)       Date:  2022-01-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.